Lv53
942 积分 2023-08-20 加入
Re-evaluating the concept of remission in type 2 diabetes: a call for patient-centric approaches
28天前
已关闭
Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial
1个月前
已完结
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial
1个月前
已完结
Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
1个月前
已完结
The ongoing evolution of basal insulin therapy over 100 years and its promise for the future
1个月前
已完结
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial
1个月前
已完结
Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
1个月前
已完结
Effect of deprescribing in elderly patients with type 2 diabetes: iDegLira might improve quality of life
1个月前
已完结
Real‐world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus
1个月前
已完结
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
1个月前
已完结
皖公网安备34019202002308
